

AMENDMENTS TO THE CLAIMS

1-14. **(Canceled)**

15. **(Previously Presented)** A method of treating or prophylactically suppressing type 2 diabetes, the method comprising administering to a mammal in need thereof a medicament comprising a sufficient amount of anakinra.

16. **(Previously Presented)** The method according to claim 15, wherein the medicament is adapted for parenteral administration.

17. **(Previously Presented)** The method according to claim 16, wherein anakinra is administered to the mammal in a dose of 0.1 to 1000mg of anakinra per kg of body weight.

18. **(Previously Presented)** The method according to claim 15, wherein the medicament further comprises pyrrolidinedithiocarbamate (PDTC).

19. **(Previously Presented)** The method according to claim 18, wherein the medicament is adapted for parenteral administration.

20. **(Previously Presented)** The method according to claim 19, wherein the anakinra is administered to the mammal in a dose of 0.1 to 1000mg of anakinra per kg of body weight.

21. **(Currently Amended)** The method according to claim 20, wherein the PSTC-PDTC is administered to the mammal in a dose of 0.1 to 1000mg of PDTC per kg or body weight.

22. **(New)** A method of treating type 2 diabetes, the method comprising administering to a mammal in need thereof a dose of 0.1 to 1000mg of anakinra per kg of body weight.

23. **(New)** The method according to claim 22, wherein the medicament is administered via parenteral administration.

24. **(New)** The method according to claim 22, wherein the medicament further comprises pyrrolidinedithiocarbamate (PDTC).
25. **(New)** The method according to claim 24, wherein the medicament is administered by parenteral administration.
26. **(New)** The method according to claim 25, wherein the PDTC is administered to the mammal in a dose of 0.1 to 1000mg of PDTC per kg or body weight.